ABIONYX Pharma SA (ABNX.PA) Stock Price

€2.1 0%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    7

  • Fundamental

    8

  • Technical

    8

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on ABIONYX Pharma SA, AI stock picks, stock alerts and much more.

Sign up

ABNX.PA AI Stock Analysis

AI stock analysis for ABNX.PA is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like ABIONYX Pharma SA (ABNX.PA) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

ABIONYX Pharma SA (ABNX.PA) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of ABIONYX Pharma SA (ABNX.PA), currently trading at €2.1, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About ABNX.PA

LSE

  • ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.

  • Symbol

    ABNX.PA

  • Market

    EURONEXT

  • Industry

    Biotechnology

  • Market Cap

    72.8M

Similar Stocks

VLA.PA Valneva SE
VLA.PA		 €5.05
2.4%
5
TUB.BR Financière de Tubize SA
TUB.BR		 €160.6
0.4%
8
OSE.PA OSE Immunotherapeutics SA
OSE.PA		 €6.32
0.5%
6
UCB.BR UCB SA
UCB.BR		 €197.3
0.9%
6
IPH.PA Innate Pharma S.A.
IPH.PA		 €2.01
1.9%
5

News

No news articles.

ABNX.PA Alternative Data

Web Traffic

ABIONYX Pharma SA receives an estimated 1138 monthly visitors to abionyx.com.

  • Web Traffic

    1138

  • Change from Previous Month

    5.4%

  • 3 Month Change

    29.5%

  • YoY Change

    29.5%

Job Postings

ABIONYX Pharma SA currenly has an estimated 0 open job postings.

  • Job Postings

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Reddit Mentions

ABIONYX Pharma SA has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Twitter Followers

ABIONYX Pharma SA has 255 Twitter Followers on its main Twitter (also known as X) account, which is up by 1.2% over the last month.

  • Twitter Followers

    255

  • Daily Change

    0%

  • 1 Month Change

    1.2%

  • 3 Month Change

    4.9%

LinkedIn Followers

1,586 are following ABIONYX Pharma SA on LinkedIn, up by 2.6% over the last month.

  • LinkedIn Followers

    1586

  • Daily Change

    2.6%

  • 1 Month Change

    2.6%

  • 3 Month Change

    5.8%

LinkedIn Employees

According to LinkedIn, ABIONYX Pharma SA has 9 employees, up by 12.5% over the last month.

  • LinkedIn Employees

    9

  • Daily Change

    12.5%

  • 1 Month Change

    12.5%

  • 3 Month Change

    12.5%

News Mentions

ABIONYX Pharma SA was mentioned 0 times in the news yesterday.

  • News Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

ABNX.PA Financials

ABNX.PA Key Metrics

  • Total Revenue

    €2.3M

  • Net Income

    -€2.3M

  • Earnings per Share

    -€0.072

  • Free cash flow

    -€1.7M

  • EBITDA

    €2.1M

  • EBITDA Ratio

    0.909131

  • Total Assets

    €13.5M

ABNX.PA 2-year Revenue & Income
ABNX.PA 2-year Free Cash Flow

ABNX.PA Technicals

ABNX.PA SMA
ABNX.PA RSI

FAQ

What's the current price of ABIONYX Pharma SA (ABNX.PA) Stock?
The price of an ABIONYX Pharma SA (ABNX.PA) share is €2.1.

What's the market cap of ABIONYX Pharma SA?
The current market cap of ABIONYX Pharma SA is 72.8M.

Should I buy or sell ABNX.PA?
Multiple alternative data signals suggest that ABIONYX Pharma SA stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.

Is ABIONYX Pharma SA a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in ABIONYX Pharma SA stock. The bullish indicators suggest that ABIONYX Pharma SA's growth prospects and market position may lead to a positive performance in the foreseeable future.

Is now a good time to buy ABIONYX Pharma SA (ABNX.PA) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying ABIONYX Pharma SA stock, given the bullish outlook.

What are some stocks similar to ABIONYX Pharma SA (ABNX.PA) that investors often compare it to?
ABIONYX Pharma SA (ABNX.PA) is often compared to similar stocks such as Valneva SE, Financière de Tubize SA, OSE Immunotherapeutics SA, UCB SA and Innate Pharma S.A..

What is the forecast for ABIONYX Pharma SA's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast ABIONYX Pharma SA's stock price to be around €2.31 in 2026. Starting from the current price of €2.1, this represents a 10% change in price, indicating a bullish outlook for the stock.

How to buy ABIONYX Pharma SA (ABNX.PA) Stock?
ABIONYX Pharma SA stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy ABIONYX Pharma SA shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.